<?xml version='1.0' encoding='utf-8'?>
<document id="25845867"><sentence text="Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine."><entity charOffset="133-143" id="DDI-PubMed.25845867.s1.e0" text="cipargamin" /><entity charOffset="149-160" id="DDI-PubMed.25845867.s1.e1" text="piperaquine" /><pair ddi="false" e1="DDI-PubMed.25845867.s1.e0" e2="DDI-PubMed.25845867.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s1.e0" e2="DDI-PubMed.25845867.s1.e1" /></sentence><sentence text="KAE609 represents a new class of potent, fast-acting, schizonticidal antimalarials" /><sentence text=" This study investigated the safety and pharmacokinetics of KAE609 in combination with the long-acting antimalarial piperaquine (PPQ) in healthy volunteers"><entity charOffset="116-127" id="DDI-PubMed.25845867.s3.e0" text="piperaquine" /><entity charOffset="129-132" id="DDI-PubMed.25845867.s3.e1" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s3.e0" e2="DDI-PubMed.25845867.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s3.e0" e2="DDI-PubMed.25845867.s3.e1" /></sentence><sentence text=" A two-way pharmacokinetic interaction was hypothesized for KAE609 and PPQ, as both drugs are CYP3A4 substrates and inhibitors"><entity charOffset="71-73" id="DDI-PubMed.25845867.s4.e0" text="PPQ" /></sentence><sentence text=" The potential for both agents to affect the QT interval was also assessed" /><sentence text=" This was an open-label, parallel-group, single-dose study with healthy volunteers" /><sentence text=" Subjects were randomized to four parallel dosing arms with five cohorts (2:2:2:2:1), receiving 75 mg KAE609 plus 320 mg PPQ, 25 mg KAE609 plus 1,280 mg PPQ, 25 mg KAE609 alone, 320 mg PPQ alone, or 1,280 mg PPQ alone"><entity charOffset="121-123" id="DDI-PubMed.25845867.s7.e0" text="PPQ" /><entity charOffset="153-155" id="DDI-PubMed.25845867.s7.e1" text="PPQ" /><entity charOffset="185-187" id="DDI-PubMed.25845867.s7.e2" text="PPQ" /><entity charOffset="208-210" id="DDI-PubMed.25845867.s7.e3" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e0" e2="DDI-PubMed.25845867.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e0" e2="DDI-PubMed.25845867.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e0" e2="DDI-PubMed.25845867.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e0" e2="DDI-PubMed.25845867.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e1" e2="DDI-PubMed.25845867.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e1" e2="DDI-PubMed.25845867.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e1" e2="DDI-PubMed.25845867.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e2" e2="DDI-PubMed.25845867.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25845867.s7.e2" e2="DDI-PubMed.25845867.s7.e3" /></sentence><sentence text=" Triplicate electrocardiograms were performed over the first 24 h after dosing, with single electrocardiograms at other time points" /><sentence text=" Routine safety (up to 89 days) and pharmacokinetic (up to 61 days) assessments were performed" /><sentence text=" Of the 110 subjects recruited, 99 completed the study" /><sentence text=" Coadministration of PPQ had no overall effect on exposure to KAE609, although 1,280 mg PPQ decreased the KAE609 maximum concentration (Cmax) by 17%"><entity charOffset="21-23" id="DDI-PubMed.25845867.s11.e0" text="PPQ" /><entity charOffset="88-90" id="DDI-PubMed.25845867.s11.e1" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s11.e0" e2="DDI-PubMed.25845867.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s11.e0" e2="DDI-PubMed.25845867.s11.e1" /></sentence><sentence text=" The group that received 25 mg KAE609 plus 1,280 mg PPQ showed a 32% increase in the PPQ area under the concentration-time curve from 0 to infinity (AUCinf), while the group that received 75 mg KAE609 plus 320 mg PPQ showed a 14% reduction"><entity charOffset="52-54" id="DDI-PubMed.25845867.s12.e0" text="PPQ" /><entity charOffset="85-87" id="DDI-PubMed.25845867.s12.e1" text="PPQ" /><entity charOffset="213-215" id="DDI-PubMed.25845867.s12.e2" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s12.e0" e2="DDI-PubMed.25845867.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s12.e0" e2="DDI-PubMed.25845867.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25845867.s12.e0" e2="DDI-PubMed.25845867.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25845867.s12.e1" e2="DDI-PubMed.25845867.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25845867.s12.e1" e2="DDI-PubMed.25845867.s12.e2" /></sentence><sentence text=" Mean changes from baseline in the QT interval corrected by Fridericia's method (QTcF) and the QT interval corrected by Bazett's method (QTcB) with PPQ were consistent with its known effects"><entity charOffset="148-150" id="DDI-PubMed.25845867.s13.e0" text="PPQ" /></sentence><sentence text=" PPQ but not KAE609 exposure correlated with corrected QT interval (QTc) increases, and KAE609 did not affect the PPQ exposure-QTc relationship"><entity charOffset="1-3" id="DDI-PubMed.25845867.s14.e0" text="PPQ" /><entity charOffset="114-116" id="DDI-PubMed.25845867.s14.e1" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s14.e0" e2="DDI-PubMed.25845867.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s14.e0" e2="DDI-PubMed.25845867.s14.e1" /></sentence><sentence text=" The QTcF effect for PPQ (least-squares estimate of the difference in mean maximal changes from baseline of 7"><entity charOffset="21-23" id="DDI-PubMed.25845867.s15.e0" text="PPQ" /></sentence><sentence text="47 ms [90% confidence interval, 3" /><sentence text="55 to 11" /><sentence text="4 ms]) was consistent with the criteria for a positive thorough QT study" /><sentence text=" No subject had QTcF or QTcB values of &gt;500 ms" /><sentence text=" Both drugs given alone or in combination were well tolerated, with no deaths, serious adverse events (AEs), or severe AEs reported" /><sentence text=" Most AEs were mild; upper respiratory tract infections, headache, diarrhea, and oropharyngeal pain were most common" /><sentence text=" PPQ and KAE609 coadministration had no relevant effect on exposure to either agent, and KAE609 did not affect or potentiate the known effects of PPQ on cardiac conduction"><entity charOffset="1-3" id="DDI-PubMed.25845867.s22.e0" text="PPQ" /><entity charOffset="146-148" id="DDI-PubMed.25845867.s22.e1" text="PPQ" /><pair ddi="false" e1="DDI-PubMed.25845867.s22.e0" e2="DDI-PubMed.25845867.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25845867.s22.e0" e2="DDI-PubMed.25845867.s22.e1" /></sentence><sentence text="" /></document>